A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata
No medical therapy is currently available for the long-term treatment of abnormal uterine
bleeding associated with uterine fibroids in women and many women must resort to surgery for
relief. The objective of this study is to determine the long-term safety of asoprisnil 10
and 25 mg administered daily for 18 months to subjects with symptomatic uterine leiomyomata
who completed the 6 month Study C02-037. The safety endpoints for this study will be based
on assessments of the endometrium, ovarian cysts, lipid profiles, adverse events and
clinical laboratory evaluations.
Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was
prematurely discontinued for all subjects. To ensure safety, subjects will remain on study
and will undergo scheduled study procedures. In most subjects, endometrial changes
reversed after asoprisnil discontinuation.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Long Term Safety
Throughout 18 month treatment period
Yes
Medical Director
Study Chair
Abbott
United States: Food and Drug Administration
C03-062
NCT00156208
April 2004
December 2006
Name | Location |
---|